![Shelby Walker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shelby Walker
General Counsel bei
ABSCI CORPORATION
Vermögen: 67 102 $ am 31.05.2026
Profil
Shelby J.
Walker is Director at Becker Capital Management, Inc. since 2023.
Ms. Walker is Chief Legal Officer at Absci Corp.
starting in 2024.
Former roles include Chief IP Counsel, VP & Associate General Counsel at Dyax Corp.
from 2010 to 2016; General Counsel at Gingko Bioworks from 2016 to 2018; Senior Vice President & Head-Intellectual Property at CRISPR Therapeutics AG from 2018 to 2023; Secretary, Senior Vice President & General Counsel at Korro Bio, Inc. from 2023 to 2024; Senior Patent Attorney at ZymoGenetics, Inc.; and IP Counsel at Novo Nordisk Pharma AG.
Education includes graduate degrees from The Johns Hopkins University and the University of New Hampshire School of Law, and an undergraduate degree from Worcester Polytechnic Institute.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ABSCI CORPORATION 0.01% | 31.03.2026 | 9’941 ( 0.01% ) | 67 102 $ | 31.05.2026 |
Aktive Positionen von Shelby Walker
| Unternehmen | Position | Beginn |
|---|---|---|
| ABSCI CORPORATION | General Counsel | 01.06.2024 |
Becker Capital Management, Inc.
 Becker Capital Management, Inc. Investment ManagersFinance BCM implements an integrated research process that is focused on building efficient and durable portfolios appropriate to clients’ specific needs across all strategies. The firm focuses on underlying asset quality and pays close attention to valuation, irrespective of asset class. The research team merges a bottom-up asset selection process with a top-down portfolio construction process to maximize risk-adjusted returns within the constraints of clients’ circumstances. An asset may be sold if it becomes fairly or overly valued in the firm’s judgement, a better opportunity is identified, or the underlying investment thesis for asset is deemed no longer valid. Moreover, if an asset does not fulfill its role within the portfolio, or if its risk profile changes materially, it may be sold as well. | Trading-Equity | 01.01.1997 |
Ehemalige bekannte Positionen von Shelby Walker
| Unternehmen | Position | Ende |
|---|---|---|
| CRISPR THERAPEUTICS AG | Corporate Officer/Principal | 01.04.2023 |
Gingko Bioworks | General Counsel | 01.03.2018 |
| DYAX CORP. | General Counsel | 01.06.2016 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
Ausbildung von Shelby Walker
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
49
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Becker Capital Management, Inc.
Becker Capital Management, Inc. Investment ManagersFinance BCM implements an integrated research process that is focused on building efficient and durable portfolios appropriate to clients’ specific needs across all strategies. The firm focuses on underlying asset quality and pays close attention to valuation, irrespective of asset class. The research team merges a bottom-up asset selection process with a top-down portfolio construction process to maximize risk-adjusted returns within the constraints of clients’ circumstances. An asset may be sold if it becomes fairly or overly valued in the firm’s judgement, a better opportunity is identified, or the underlying investment thesis for asset is deemed no longer valid. Moreover, if an asset does not fulfill its role within the portfolio, or if its risk profile changes materially, it may be sold as well. | Finance |
Dyax Corp.
 Dyax Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of novel biotherapeutics | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Worcester Polytechnic Institute
 Worcester Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk Pharma AG
 Novo Nordisk Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures and markets insulin and diabetes products | Health Technology |
CRISPR Therapeutics AG
 CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
University of New Hampshire School of Law
 University of New Hampshire School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Absci Corp.
 Absci Corp. BiotechnologyHealth Technology Engages in development of cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry | Health Technology |
Gingko Bioworks |
